The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Non-Malignant Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
CAR-T Meeting 2025 | The standard of care for autoimmune hemolytic anemia and how this may change with novel therapies
Ulrich Jäger, MD, Medical University of Vienna, Vienna, Austria, comments on the current standard of care for autoimmune hemolytic anemia, noting that warm autoimmune hemolytic anemia is typically treated with first-line steroids. In contrast, cold autoimmune hemolytic anemia is addressed with B-cell-directed therapies such as CD20-targeting antibodies. Prof. Jäger highlights that the treatment landscape for these diseases will change with emerging novel agents and therapeutic strategies, and new EHA guidelines will be released to reflect these changes. This interview took place at the EHA-EBMT 7th European CAR T-cell Meeting, held in Strasbourg, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (AI-generated)
The standard of care has to be divided, of course, between cold and warm autoimmune hemolytic anemia. For warm, it’s still first-line steroids. For cold, it’s more B-cell directed therapies like CD20 antibodies, where we eradicate the disease. But we are moving.
So as I alluded before, for the warm we have other inhibitors that we can use...
The standard of care has to be divided, of course, between cold and warm autoimmune hemolytic anemia. For warm, it’s still first-line steroids. For cold, it’s more B-cell directed therapies like CD20 antibodies, where we eradicate the disease. But we are moving.
So as I alluded before, for the warm we have other inhibitors that we can use. And for the cold we are particularly moving into the field of complement inhibition. There are approved complement inhibitors like sutimlimab, but there are also others which are currently studied. So the guidelines are somehow rewritten at this point. And by the way, I would like to mention that there will be an EHA guideline, which is curated by our colleagues from Italy, Bruno Fattizzo, but it will cover all experts in Europe. And these guidelines will probably be out this year, maybe next year, so look for them.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
